Oncology Med Expands Its Prostate Brachytherapy Program With New Ambulatory Surgery Center Contracts in the Northeast as It Cont
April 02 2008 - 7:00AM
Marketwired
PITTSBURGH, PA a Pittsburgh-based cancer treatment solutions
group, announced today that it has signed new multiple year
exclusive contracts in the Northeast; particularly in New York and
Massachusetts. These exclusive multi-year contracts in these new
markets will have Oncology Med providing physics and full turnkey
prostate cancer brachytherapy services, equipment, staff, and
radionuclide seed management to ambulatory surgery centers who
either have urologists who utilize and/or who are invested in the
ambulatory surgery center.
According to William Walker, Ph.D., Oncology Med's CEO and
founder, "As I have previously stated, these new contracts are
additional client sites of the many that we hope to announce to our
investors and other interested parties over the next several
quarters centered around one of our new turnkey programs for cancer
treatment."
Jack Sloan, Vice President of Business Development, added, "We
consider our company to be unique in the market as opposed to other
turnkey cancer providers who are management companies who
sub-contract out the necessary professional and technical pieces of
their programs to subcontractors for the requisite components to
provide a full turnkey program. As a result of this structure they
have to charge higher fees to the client to cover the management
cost. Oncology Med is a full-service clinical company to which many
management companies have turned in the past to fulfill their
obligations in providing turnkey cancer solutions. Therefore,
Oncology Med can enter the competitive arena of turnkey cancer
solutions with all services under one roof, provide faster
installation of new programs, equipment, services, and staff, and
do so at a lower cost to the client than our competitors."
Oncology Med's new approach to the market allows it more control
of its profits and future by securing additional multi-year
contracts directly with large and small medical systems, ambulatory
surgery centers, and cancer institutes rather than rely on 'per
click' usage of its services by management companies with no long
term contractual commitment to Oncology Med and its programs and
services.
"We will still contract and seek out relationships with key
cancer management companies and other medical facility groups;
however, we will expect more long-term commitment from the
management companies we choose to contract with and align our
resources going forward for a more equitable and financially
beneficial contractual relationship for both companies," continued
Sloan.
"With the changes in reimbursement from the Center for Medicare
and Medicare Services (CMS) which were instituted in January of
2008 for prostate brachytherapy services in the ambulatory surgery
centers (ASCs) and the exemption given to physician-owned ASCs, we
have seen a marked increase in the interest shown by many centers
across the country to add prostate cancer brachytherapy to their
list of offered procedures," Walker contended.
"Under the new reimbursement guidelines established by CMS,
prostate cancer brachytherapy is an excellent additional revenue
stream for most ambulatory surgery centers where the ASC either has
urology participation or chooses to add urology services and are
seeking additional value for its investors and shareholders," Sloan
stated.
Oncology Med's depth of staff, expertise, and technological
advanced planning systems and equipment positions the company to be
sought out by ambulatory surgery centers, hospitals, medical
systems, and cancer centers who seek to expand and/or improve
services without the burden and cost of bringing on additional
internal staff that are not fully necessary or which lack the
experience and expertise of those provided through Oncology
Med.
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation treatments to
cancer patients. Current services facilitate radiation treatment
programs ranging from external beam radiation to more advanced
radiation treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact: William Walker, Ph.D. Oncology
Med, Inc. 1-504-822-5161
Bellatora (PK) (USOTC:ECGR)
Historical Stock Chart
From Apr 2024 to May 2024
Bellatora (PK) (USOTC:ECGR)
Historical Stock Chart
From May 2023 to May 2024
